Results 61 to 70 of about 64,427 (282)
Generation of orthotopic patient-derived xenografts from gastrointestinal stromal tumor. [PDF]
, 2014 BackgroundGastrointestinal stromal tumor (GIST) is the most common sarcoma and its treatment with imatinib has served as the paradigm for developing targeted anti-cancer therapies.
Babicky, Michele L +10 more
core +3 more sources
Journal of Veterinary Internal Medicine, Volume 39, Issue 4, July/August 2025.ABSTRACT A 21‐year‐old miniature donkey gelding was evaluated for pruritus, inappetence, hypertriglyceridemia, and alopecia of 2 weeks' duration. Hematology showed moderate eosinophilia, severe hypertriglyceridemia, and moderately increased liver enzyme activities. Cytologic evaluation of peritoneal fluid identified an eosinophilic transudate.
Carla K. Enriquez +4 more
wiley +1 more source
Maxillofacial Plastic and Reconstructive Surgery, 2017 Background Imatinib mesylate is an inhibitor of the tyrosine kinase Bcr–Abl and a first-line treatment for Philadelphia chromosome-positive chronic myeloid leukaemia (CML).
Gian Paolo Bombeccari +6 more
doaj +1 more source
Ageing is a risk factor in imatinib mesylate cardiotoxicity
European Journal of Heart Failure, 2014 Chemotherapy‐induced heart failure is increasingly recognized as a major clinical challenge. Cardiotoxicity of imatinib mesylate, a highly selective and effective anticancer drug belonging to the new class of tyrosine kinase inhibitors, is being reported
Wael M Maharsy +4 more
semanticscholar +1 more source
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein [PDF]
, 2013 Patients with chronic myeloid leukemia in whom tyrosine kinase inhibitors (TKIs) fail often present mutations in the BCR-ABL catalytic domain. We noticed a lack of substitutions involving 4 amino acids (E286, M318, I360, and D381) that form hydrogen ...
Alessandro Pandini +11 more
core +1 more source
SUCCINATE DEHYDROGENASE SUBUNIT B DEFICIENT PEDIATRIC GIST
Hematology, Transfusion and Cell Therapy, 2022 Case report Gastrointestinal stromal tumors (GISTs) occur exceedingly rare in children and adolescents. Eighty five percent of pediatric GISTs and 15 % of adult GISTs lack oncogenic mutations in KIT and PDGFRA.
Melek Yaman Ortakoylu +5 more
doaj
Indian Journal of Pathology and Microbiology, 2013 Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the intestinal tract. In patients with locally advanced and/or metastatic GIST, the introduction of tyrosine kinase inhibitor, imatinib mesylate, has transformed the ...
Mukul Vij, Susama Patra, Mohamed Rela
doaj +1 more source
Management of imatinib-resistant CML patients [PDF]
, 2007 Imatinib has had marked impact on outcomes in chronic myelogenous leukemia (CML) patients for all stages of the disease and is endorsed by international treatment guidelines as the first line option.
Branford S +21 more
core +1 more source
Clinical presentation and treatment of gastrointestinal stromal tumors. [PDF]
, 2006 AIMS AND BACKGROUND: Gastrointestinal stromal tumors (GISTs), although rare, are the most common mesenchymal neoplasms affecting the gastrointestinal tract.
CIPOLLA, Calogero +10 more
core +1 more source
Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance [PDF]
, 2011 BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients.
Aamer Aleem +19 more
core +1 more source